Back to results
US 11,442,068 B2Granted
Method for diagnosing and treating fibromyalgia
AssigneeEpicgenetics, Inc.
InventorBruce S. Gillis
Life of this patent
Estimating the term…
Abstract
The invention provides methods, kits and reagents for diagnosing fibromyalgia (FM) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive/indicative of FM in the individual.
Claims17
A method of treating fibromyalgia (FM) in an individual, the method comprising:
- (a) stimulating a peripheral blood mononuclear cell (PBMC) sample obtained from an individual previously diagnosed with FM with one or more mitogens;
- (b) determining expression levels in the PBMC sample of at least four cytokines selected from the group consisting of interleukin 5 (IL5), interleukin 6 (IL6), interleukin 8 (IL8), interleukin 10 (IL 10), interferon-γ (IFN-γ), monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and macrophage inflammatory protein-1β (MIP-1β) at the protein level by an antibody bead-based capture assay, wherein the bead-based capture assay comprises beads derivatized with antibodies specific to the at least four cytokines;
- (c) comparing the determined levels of protein expression to the expression levels of the at least four cytokines in a control sample;
- (d) identifying the individual as having the at least four cytokines expression levels decreased by at least about 1.5 times in the PBMC sample obtained from the individual previously diagnosed with FM as compared to the expression levels of the control sample;
- and
- (e) administering to the identified individual an effective amount of a FM standard of care selected from the group consisting of duloxetine, pregabalin, gabapentin and milnacipran.
3 more elements
Dependencies are inferred from the claim text.